Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Anesthesiology ; 120(5): 1109-1117, 2014 May.
Article in English | MEDLINE | ID: mdl-24755784

ABSTRACT

BACKGROUND: Cardiac overexpression of the ß-adrenoreceptor (ßAR)-coupled stimulatory G-protein subunit Gαs enhances inotropic responses to adrenergic stimulation and improves survival in mice under ßAR blockade. The authors recently identified three common haplotypes in the GNAS gene encoding Gαs, with the greatest Gαs protein expression and signal transduction in haplotype *3 carriers and less in haplotype *2 and *1 carriers. The authors tested the hypothesis that these GNAS variants result in altered mortality in patients after coronary artery bypass graft surgery, particularly in those receiving ßAR blockade. METHODS: This prospective analysis included 1,627 European ancestry patients undergoing primary coronary artery bypass graft surgery. Patients were genotyped for two GNAS haplotype tagging single-nucleotide polymorphisms defining three major haplotypes. Up to 5-yr all-cause mortality was estimated using a Cox proportional hazard model; hazard ratios and 95% CIs were calculated while adjusting for demographics, clinical covariates, and the new EuroSCORE II. RESULTS: Univariate analysis revealed haplotype-dependent 5-yr mortality rates (*1/*1: 18.9%, *2/*1: 13.7%, *2/*2: 9.3%, *3/*1: 10.6%, *3/*2: 9.1%, and *3/*3: 9.6%; P = 0.0006). After adjustment for other predictors of death, homozygote haplotype *1 carriers showed a doubled risk for death (hazard ratio, 2.2; 95% CI, 1.2 to 3.8; P = 0.006). Considering only patients receiving ßAR blockers (n = 1,267), the adjusted risk of death even tripled (hazard ratio, 3.0; 95% CI, 1.5 to 6.1; P = 0.002). CONCLUSIONS: GNAS haplotypes independently associate with an increased risk of death after primary coronary artery bypass graft surgery. These results are most pronounced in patients receiving ßAR blockers, strengthening the rationale for personalized treatment, to decrease medication side effects and improve outcomes.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Coronary Artery Bypass/mortality , GTP-Binding Protein alpha Subunits, Gs/genetics , Genetic Variation/genetics , Haplotypes/genetics , Adult , Aged , Aged, 80 and over , Chromogranins , Cohort Studies , Coronary Artery Bypass/adverse effects , Female , Humans , Longitudinal Studies , Male , Middle Aged , Polymorphism, Single Nucleotide/genetics , Prospective Studies , Registries , Survival Rate/trends , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...